This case report demonstrates an extremely elevated PCT level in a primary hepatic neuroendocrine carcinoma, and the most interesting point is that the PCT level significantly declined after each round of effective antitumor therapy. The gene discussed is CALCA; the disease is liver neuroendocrine carcinoma.